



## Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: [www.bioscmed.com](http://www.bioscmed.com)

### Pregnancy-Triggered Severe Lupus Nephritis with Pleural Effusion: A Case Report

Zaki Mahmudi Dasril<sup>1\*</sup>, Deka Viotra<sup>2</sup>

<sup>1</sup>Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

<sup>2</sup>Division of Hypertension Nephrology, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

#### ARTICLE INFO

##### Keywords:

Lupus nephritis  
Nephrotic syndrome  
Pleural effusion  
Pregnancy  
Systemic lupus erythematosus

##### \*Corresponding author:

Zaki Mahmudi Dasril

##### E-mail address:

[zakimd13@yahoo.com](mailto:zakimd13@yahoo.com)

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/bsm.v9i5.1275>

#### ABSTRACT

**Background:** Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), characterized by kidney inflammation. Pregnancy can trigger or exacerbate LN due to hormonal shifts and altered immune responses. This case highlights the challenges in diagnosing and managing pregnancy-associated LN. **Case presentation:** A 27-year-old woman presented with anasarca, malar rash, shortness of breath, and foamy urine during her first pregnancy. She had a history of SLE with previous symptoms limited to skin and joint involvement. Investigations revealed nephrotic-range proteinuria, hematuria, elevated creatinine, and positive anti-nuclear antibodies (ANA). Renal biopsy confirmed Class IV lupus nephritis. She was diagnosed with pregnancy-triggered severe LN with nephrotic syndrome, pleural effusion, and a hypercoagulable state. Treatment included high-dose corticosteroids and mycophenolate mofetil, with close monitoring of both maternal and fetal health. **Conclusion:** This case underscores the importance of recognizing and promptly managing LN in pregnancy. Early diagnosis, multidisciplinary care, and individualized treatment are crucial to optimize maternal and fetal outcomes.

#### 1. Introduction

Systemic lupus erythematosus (SLE) is a complex and multifaceted autoimmune disease characterized by its diverse clinical manifestations and unpredictable course. It affects various organ systems, including the skin, joints, kidneys, heart, and lungs, leading to a wide range of symptoms such as fatigue, fever, joint pain, skin rashes, and organ damage. The hallmark of SLE is the production of autoantibodies, which are antibodies directed against the body's own tissues and cells. These autoantibodies play a crucial role in the pathogenesis of SLE, triggering inflammation and tissue damage. Lupus nephritis (LN) is a severe and potentially life-threatening complication of SLE, affecting approximately 50-60%

of SLE patients. It is characterized by inflammation of the kidneys, leading to proteinuria, hematuria, and impaired renal function. LN is a major cause of morbidity and mortality in SLE patients, and its management remains a significant challenge for clinicians.<sup>1-4</sup>

Pregnancy in women with SLE, particularly those with LN, presents unique challenges due to the complex interplay between hormonal changes, immune responses, and disease activity. Pregnancy can trigger or exacerbate SLE activity, leading to flares of LN and other SLE manifestations. The hormonal changes during pregnancy, particularly the increase in estrogen levels, can alter the immune system and promote autoantibody production, contributing to LN

flares. Additionally, the shift from a Th1 to Th2 immune response during pregnancy can further exacerbate SLE activity. These factors contribute to a higher risk of LN flares and adverse pregnancy outcomes, including pre-eclampsia, preterm birth, and fetal loss.<sup>5-7</sup>

The management of LN in pregnancy requires a delicate balance between controlling disease activity and minimizing risks to the fetus. Treatment decisions must be individualized based on the severity of LN, the stage of pregnancy, and the overall health of the mother and fetus. Close monitoring of both maternal and fetal health is essential throughout pregnancy and postpartum.<sup>8-10</sup> This case report describes a 27-year-old woman who developed severe LN with nephrotic syndrome and pleural effusion during her first pregnancy.

## 2. Case Presentation

The patient is a 27-year-old female who presented during her second trimester of her first pregnancy with complaints of generalized swelling (anasarca), a facial rash, shortness of breath, and foamy urine. These symptoms had been gradually developing over the course of her second trimester. She had a prior history of systemic lupus erythematosus (SLE), diagnosed three years earlier, but her previous manifestations were limited to skin and joint involvement. Importantly, she was not taking any SLE-related medications at the time of this presentation. Her past medical history was significant only for SLE, and she reported no known drug allergies. There was no family history of autoimmune diseases. On physical examination, the patient appeared ill and exhibited anasarca, a malar rash characteristic of SLE, and decreased breath sounds at the bases of her lungs bilaterally, suggestive of pleural effusions. Her blood pressure was elevated at 160/100 mmHg. No organomegaly was detected upon examination of the gastrointestinal system. Laboratory investigations revealed several abnormalities. Her complete blood count showed mild normocytic normochromic anemia (hemoglobin of 10 g/dL) but normal white blood cell

and platelet counts. Urinalysis demonstrated significant proteinuria, exceeding 3 g/day, along with hematuria with more than 8 red blood cells per high power field. Blood chemistry analysis indicated elevated creatinine at 2.5 mg/dL, elevated blood urea nitrogen, and hypoalbuminemia with an albumin level of 2.0 g/dL. Additionally, her lipid profile was abnormal, with elevated cholesterol and triglyceride levels. Immunological testing confirmed the presence of autoantibodies characteristic of SLE. Her ANA profile was positive, displaying homogeneous, speckled, and nucleolar patterns. Anti-dsDNA antibodies were also positive, and complement levels were low, with decreased C3 and C4, indicating complement consumption, a common finding in active SLE. While her prothrombin time (PT) and activated partial thromboplastin time (APTT) were within the normal range, her D-dimer level was significantly elevated at 1812 ng/mL, suggesting a hypercoagulable state, a potential complication of SLE, particularly in the setting of active nephritis. Imaging studies were conducted to further assess the extent of her condition. Chest X-ray confirmed the presence of bilateral pleural effusions but did not show any evidence of infiltrates or cavitations. Renal ultrasound revealed normal kidney size and structure, with no signs of hydronephrosis or renal artery stenosis. Based on the collective findings from the patient's history, physical examination, and laboratory and imaging investigations, a primary diagnosis of pregnancy-triggered severe lupus nephritis (Class IV) was established. This diagnosis was supported by the new onset of severe renal manifestations in the context of a known history of SLE, exacerbated during pregnancy. Secondary diagnoses included systemic lupus erythematosus with moderate disease activity as assessed by the MEX-SLEDAI score of 8, nephrotic syndrome, Stage II hypertension, acute kidney injury (stage I), bilateral pleural effusions, mild normocytic normochromic anemia secondary to chronic disease, a hypercoagulable state, dyslipidemia, and hypoalbuminemia (Table 1).

The treatment of this patient with pregnancy-triggered severe lupus nephritis (Class IV) was approached in two phases: induction and maintenance, with ongoing follow-up care. The primary goal of the induction phase was to rapidly control the disease activity and alleviate the severe symptoms the patient presented with. This was achieved through a combination of immunosuppressive and supportive therapies. The patient was initially treated with high-dose intravenous methylprednisolone at a dose of 2 x 125 mg daily. This potent corticosteroid was used to induce remission by suppressing the inflammatory response driving the lupus nephritis. The intravenous route ensured rapid and maximal bioavailability of the drug. Subsequently, the treatment was transitioned to oral prednisone, starting at a dose of 16-16-8 mg daily, and gradually tapered down. This tapering strategy aimed to minimize the long-term side effects associated with high-dose corticosteroid use while maintaining disease control. In addition to corticosteroids, the patient was also started on MMF at a dose of 720 mg twice daily. MMF is an immunosuppressant that inhibits the proliferation of lymphocytes, key players in the autoimmune response underlying lupus nephritis. This combination therapy of corticosteroids and MMF is considered the standard of care for inducing remission in Class III/IV lupus nephritis. The duration of MMF treatment in the induction phase was six months. To address the patient's hypertension and provide renoprotective benefits, ramipril, an angiotensin-converting enzyme (ACE) inhibitor, was initiated at a dose of 5 mg daily. ACE inhibitors are known to reduce proteinuria and slow the progression of kidney disease, particularly in patients with lupus nephritis. Throughout the induction phase, the patient underwent close monitoring to assess the effectiveness of the treatment and to detect any potential side effects. This included daily blood pressure monitoring, urinalysis to track proteinuria and hematuria, and regular assessments for any adverse effects associated with the medications. Additionally, weekly complete blood

counts, renal function tests, and liver function tests were performed to monitor for any signs of toxicity or complications. The disease activity of SLE was also assessed monthly to guide treatment adjustments. The induction phase proved successful in controlling the patient's lupus nephritis. Her blood pressure normalized, edema subsided, and proteinuria significantly decreased, indicating improved kidney function and reduced disease activity. Once remission was achieved, the focus shifted to the maintenance phase, aiming to sustain disease control and prevent relapse. The treatment regimen was adjusted to maintain long-term remission while minimizing the risk of side effects. The MMF dose was reduced to 540 mg twice daily and continued for ongoing maintenance therapy. This lower dose aimed to provide sustained immunosuppression while reducing the potential for long-term toxicity. The oral prednisone was also continued at a low dose of 5 mg daily. This minimal dose of corticosteroid was intended to provide additional support in maintaining remission while minimizing the risk of steroid-related side effects. Hydroxychloroquine, an antimalarial drug with immunomodulatory properties, was added to the regimen at a dose of 200 mg twice daily. Hydroxychloroquine is commonly used in SLE maintenance therapy to control skin and joint manifestations and potentially prevent disease flares. Due to the potential for ocular toxicity, annual ophthalmological examinations were incorporated into the follow-up plan. During the maintenance phase, the monitoring continued, albeit at a reduced frequency. Monthly renal function tests and urinalysis were conducted to assess kidney function and disease activity, and SLE disease activity was evaluated regularly. Complete blood counts and liver function tests were performed every three months to monitor for any medication-related side effects. The maintenance therapy proved effective in stabilizing the patient's condition. Her creatinine level stabilized at 1.5 mg/dL, and proteinuria remained below 1 g/day, indicating sustained remission of her lupus nephritis. The patient was enrolled in an ongoing follow-up care

program involving a multidisciplinary team consisting of a nephrologist, rheumatologist, and obstetrician. This collaborative approach ensured comprehensive management of her lupus nephritis, SLE, and pregnancy. Regular follow-up visits were scheduled every 3-6 months to assess her renal function, blood pressure, SLE disease activity, and any potential

medication side effects. This ongoing monitoring aimed to detect any signs of disease recurrence or complications and to adjust treatment as needed to maintain long-term remission and optimize both maternal and fetal outcomes (Table 2).

Table 1. Summary of patient demographics, clinical presentation, and investigations.

Feature	Details
<b>Demographics</b>	
Age	27 years
Gender	Female
<b>Anamnesis</b>	
Chief complaints	Generalized swelling, facial rash, shortness of breath, foamy urine
History of present illness	Symptoms began gradually during the second trimester of her first pregnancy; previous history of SLE with skin and joint involvement; no SLE-related medications at presentation
Past medical history	SLE diagnosed 3 years prior
Family history	No family history of autoimmune diseases
Medications	None at presentation
Allergies	No known drug allergies
<b>Physical examination</b>	
General appearance	Ill appearing with anasarca
Skin	Malar rash
Respiratory	Bilateral pleural effusions; decreased breath sounds at the bases
Cardiovascular	Blood pressure: 160/100 mmHg
Gastrointestinal	No organomegaly
<b>Laboratory investigations</b>	
Complete blood count	Hemoglobin: 10 g/dL (mild normocytic normochromic anemia); White blood cell count: Normal; Platelet count: Normal
Urinalysis	Proteinuria >3 g/day; Hematuria (>8 red blood cells/high power field)
Blood chemistry	Creatinine: 2.5 mg/dL; Blood urea nitrogen: Elevated; Albumin: 2.0 g/dL; Cholesterol: Elevated; Triglycerides: Elevated
Immunology	ANA profile: Positive (homogeneous, speckled, and nucleolar patterns); Anti-dsDNA antibodies: Positive; Complement levels: Low C3 and C4
Coagulation profile	Prothrombin time (PT): 9.1 seconds (normal); Activated partial thromboplastin time (APTT): 31.2 seconds (normal); D-dimer: 1812 ng/mL (elevated)
<b>Imaging</b>	
Chest X-ray	Bilateral pleural effusions; no infiltrates or cavitations
Renal ultrasound	Normal kidney size and structure; no evidence of hydronephrosis or renal artery stenosis
<b>Clinical diagnosis</b>	
Primary diagnosis	Pregnancy-triggered severe lupus nephritis (Class IV)
Secondary diagnoses	Systemic lupus erythematosus with moderate disease activity (MEX-SLEDAI score of 8); Nephrotic syndrome; Stage II hypertension; Acute kidney injury (stage I); Bilateral pleural effusions; Mild normocytic normochromic anemia secondary to chronic disease; Hypercoagulable state; Dyslipidemia; Hypoalbuminemia

Table 2. Treatment and follow-up.

Phase	Treatment	Duration	Monitoring	Outcome
<b>Induction</b>				
	Intravenous methylprednisolone 2x125 mg daily, then tapered to oral prednisone 16-16-8 mg daily		Daily blood pressure, urinalysis, and assessment for side effects	
	Mycophenolate mofetil (MMF) 720 mg twice daily	6 months	Weekly complete blood count, renal function tests, and liver function tests; monthly assessment of SLE disease activity	
	Ramipril 5 mg daily			Blood pressure normalized; edema subsided; proteinuria decreased
<b>Maintenance</b>				
	MMF 540 mg twice daily	Ongoing	Monthly renal function tests, urinalysis, and assessment of SLE disease activity; every 3 months complete blood count and liver function tests	Creatinine stabilized at 1.5 mg/dL; proteinuria <1 g/day
	Prednisone 5 mg daily	Ongoing		
	Hydroxychloroquine 200 mg twice daily	Ongoing	Annual ophthalmological examination	
<b>Follow-up</b>				
	Regular follow-up with nephrologist, rheumatologist, and obstetrician	Ongoing	Every 3-6 months assessment of renal function, blood pressure, SLE disease activity, and medication side effects	

### 3. Discussion

Table 3 provides a comprehensive overview of the key concepts and findings related to pregnancy-triggered severe LN with pleural effusion. It elucidates the intricate relationship between hormonal changes, immune system modulation, clinical presentation, diagnostic challenges, management considerations,

and long-term implications of this condition. The table emphasizes the role of hormonal fluctuations during pregnancy, particularly the increase in estrogen levels, in exacerbating SLE activity and promoting LN flares. Additionally, the shift from Th1 to Th2 immunity during pregnancy, while essential for fetal tolerance, can inadvertently increase autoantibody production,

contributing to LN. The diverse symptoms of LN in pregnancy, including edema, hypertension, proteinuria, hematuria, and renal dysfunction, underscore the need for a thorough clinical evaluation. The presence of extra-renal manifestations, such as pleural effusion in this case, further highlights the potential for multi-organ involvement. The table acknowledges the diagnostic challenges posed by overlapping symptoms between LN and other pregnancy complications, such as pre-eclampsia. It emphasizes the importance of renal biopsy in confirming the diagnosis and classifying LN, guiding treatment decisions. The table underscores

the delicate balance required in managing LN during pregnancy, weighing the benefits of controlling disease activity against the potential risks to the fetus. It stresses the importance of a multidisciplinary approach, involving nephrologists, rheumatologists, obstetricians, and other healthcare professionals, to optimize maternal and fetal outcomes. The table acknowledges the risk of LN flares even after successful pregnancy, emphasizing the need for ongoing monitoring and follow-up care. It also highlights the importance of long-term monitoring to detect and manage potential complications, such as chronic kidney disease (Table 3).<sup>11,12</sup>

Table 3. Concepts and key findings in pregnancy-triggered severe lupus nephritis with pleural effusion.

Concept	Key findings
<b>Pregnancy as a Trigger for LN</b>	
Hormonal influence	Increased estrogen levels during pregnancy can exacerbate SLE activity and promote LN flares.
Immune system modulation	The shift from Th1 to Th2 immunity in pregnancy can increase autoantibody production, contributing to LN.
<b>Clinical presentation of LN in pregnancy</b>	
Diverse symptoms	Can present with a wide range of symptoms, including edema, hypertension, proteinuria, hematuria, and renal dysfunction.
Extra-renal manifestations	Pleural effusion, as seen in this case, can occur due to hypoalbuminemia or serositis.
<b>Diagnostic challenges</b>	
Overlapping symptoms	Symptoms of LN can mimic those of other pregnancy complications, such as pre-eclampsia.
Importance of renal biopsy	Renal biopsy is crucial for confirming the diagnosis and classifying LN, guiding treatment decisions.
<b>Management considerations</b>	
Balancing maternal and fetal risks	Treatment must be tailored to control disease activity while minimizing risks to the fetus.
Multidisciplinary care	Requires close collaboration between nephrologists, rheumatologists, obstetricians, and other healthcare professionals.
<b>Prognosis and long-term implications</b>	
Risk of flares	LN can recur or progress, even after a successful pregnancy.
Importance of follow-up	Long-term monitoring is crucial to detect and manage complications, such as chronic kidney disease.

Pregnancy in women with systemic lupus erythematosus (SLE), particularly those with lupus nephritis (LN), presents a unique set of challenges due to the intricate interplay between hormonal changes, altered immune responses, and the underlying

disease activity. This complex interplay can significantly impact both maternal and fetal outcomes, necessitating careful monitoring and management throughout the pregnancy and postpartum period. Pregnancy is associated with profound hormonal

changes, most notably a significant increase in estrogen levels. While these hormonal shifts are essential for maintaining a healthy pregnancy, they can also influence the immune system and exacerbate autoimmune diseases like SLE. Estrogen is known to have immunomodulatory effects, and its increased levels during pregnancy can promote inflammation and autoantibody production, potentially triggering or worsening LN flares. Studies have shown a correlation between estrogen levels and SLE disease activity, with higher estrogen levels associated with increased risk of flares. The exact mechanisms by which estrogen influences SLE activity are complex and not fully understood, but they are thought to involve multiple pathways. Estrogen can stimulate B cells, which are responsible for producing antibodies, including autoantibodies that attack the body's own tissues in SLE. This increased autoantibody production can contribute to inflammation and tissue damage in the kidneys, leading to LN flares. Estrogen can influence the production of cytokines, which are signaling molecules that play a crucial role in the immune response. Some cytokines promote inflammation, while others suppress it. Estrogen can shift the balance towards pro-inflammatory cytokines, contributing to SLE activity. T cells are another type of immune cell that plays a crucial role in SLE. Estrogen can affect T cell function, potentially promoting autoimmunity and inflammation. During pregnancy, the maternal immune system undergoes significant changes to accommodate the developing fetus. One of the key changes is a shift from a Th1 to a Th2 immune response. Th1 responses are characterized by the production of pro-inflammatory cytokines, while Th2 responses promote antibody production and suppress cell-mediated immunity. This shift towards a Th2-dominant immune response is essential for preventing rejection of the fetus, which is recognized as foreign by the maternal immune system. However, this shift in immune balance can inadvertently exacerbate SLE activity. SLE is associated with a Th2-dominant immune response, and the further enhancement of Th2 immunity during

pregnancy can promote autoantibody production and inflammation, potentially triggering LN flares. The clinical presentation of LN in pregnancy can vary widely, depending on the severity of the disease and the presence of other complications. Some women may experience only mild proteinuria, while others may develop severe nephrotic syndrome or even renal failure. The presence of extra-renal manifestations, such as pleural effusion in this case, further complicates the clinical picture. Proteinuria is a hallmark of LN and is often the first sign of kidney involvement. Proteinuria can range from mild to severe, and in severe cases, it can lead to nephrotic syndrome, characterized by heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Hematuria refers to the presence of blood in the urine, which can be microscopic or macroscopic. Hematuria can be a sign of kidney inflammation and damage. Hypertension elevated blood pressure is a common finding in LN and can contribute to kidney damage and other complications, such as pre-eclampsia. Renal dysfunction refers to impaired kidney function, which can manifest as elevated creatinine and blood urea nitrogen levels. In severe cases, renal dysfunction can progress to renal failure, requiring dialysis or kidney transplantation. LN can also affect other organs, leading to extra-renal manifestations such as pleural effusion, pericarditis, skin rashes, arthritis, and neurological symptoms. The diagnosis of LN in pregnancy can be challenging due to the overlapping symptoms with other pregnancy complications, such as pre-eclampsia. Both conditions can present with hypertension, proteinuria, and edema, making it difficult to differentiate them clinically. Therefore, a comprehensive evaluation is essential to establish the correct diagnosis. Urinalysis is a simple and non-invasive test that can detect proteinuria and hematuria, which are hallmark signs of LN. Blood tests can assess kidney function, measure inflammation markers, and detect autoantibodies associated with SLE. Renal biopsy is the gold standard for confirming the diagnosis and classifying LN. Renal biopsy involves obtaining a small tissue sample from

the kidney, which is then examined under a microscope to assess the extent and type of kidney damage. The management of LN in pregnancy requires a delicate balance between controlling disease activity and minimizing risks to the fetus. Treatment decisions must be individualized based on the severity of LN, the stage of pregnancy, and the overall health of the mother and fetus. The severity of LN is assessed based on the degree of proteinuria, renal dysfunction, and the presence of extra-renal manifestations. The stage of pregnancy influences treatment decisions, as some medications may be contraindicated during certain trimesters. The overall health of the mother, including any comorbidities, is taken into consideration when choosing treatment options. The potential risks to the fetus, such as teratogenicity and growth restriction, are carefully evaluated before initiating any treatment. The mainstay of treatment for LN in pregnancy is immunosuppression, typically with corticosteroids and other immunosuppressive medications. Corticosteroids, such as prednisone, are potent anti-inflammatory drugs that can effectively control LN flares. However, they can also have significant side effects, including gestational diabetes, hypertension, and pre-eclampsia. Therefore, the lowest effective dose of corticosteroids should be used, and the duration of treatment should be minimized. Other immunosuppressive medications, such as azathioprine and mycophenolate mofetil (MMF), may be used in cases of severe or refractory LN. However, these medications can also have potential adverse effects on the fetus, including teratogenicity and growth restriction. Therefore, their use should be carefully considered and monitored. In addition to immunosuppression, other supportive measures may be necessary to manage LN in pregnancy. Hypertension is a common complication of LN and can contribute to kidney damage and other complications, such as pre-eclampsia. Therefore, blood pressure control is essential in managing LN in pregnancy. Edema, or swelling, is another common symptom of LN and can be uncomfortable and debilitating. Edema management may involve lifestyle modifications, such

as elevating the legs and wearing compression stockings, as well as medications, such as diuretics. Regular monitoring of fetal growth and well-being is essential to detect any potential complications, such as growth restriction or fetal distress. Close monitoring of both maternal and fetal health is crucial throughout pregnancy and postpartum in women with LN. Regular follow-up visits with the healthcare team are essential to assess disease activity, monitor treatment response, and manage any potential complications. Postpartum care is equally important, as LN can recur or progress after delivery. Women with LN should continue to be monitored closely for signs of disease activity and receive appropriate treatment as needed. Long-term follow-up care is essential to prevent chronic kidney disease and other complications.<sup>13-15</sup>

The case of the 27-year-old pregnant woman experiencing a severe lupus nephritis (LN) flare vividly illustrates the intricate diagnostic and therapeutic challenges inherent in managing this condition during pregnancy. The overlapping symptoms of LN with other pregnancy complications, the potential risks of medications to both the mother and fetus, and the dynamic nature of the disease necessitate a nuanced and individualized approach to care. Distinguishing LN flares from other pregnancy-related complications, such as pre-eclampsia, poses a significant diagnostic challenge. Both conditions can manifest with similar clinical features, including hypertension, proteinuria, and edema. This overlap can lead to diagnostic uncertainty and delay in appropriate treatment, potentially jeopardizing both maternal and fetal well-being. In this particular case, the patient's presentation with nephrotic syndrome, characterized by heavy proteinuria, hypoalbuminemia, and edema, along with the presence of pleural effusion and a hypercoagulable state, raised a strong suspicion for LN. However, her presentation could also have been attributed to pre-eclampsia, a serious pregnancy complication characterized by hypertension and proteinuria. To differentiate between these two conditions, a thorough clinical assessment and



targeted investigations are crucial. In addition to evaluating the patient's clinical presentation and medical history, laboratory tests, such as blood and urine tests, can provide valuable information. However, the gold standard for confirming the diagnosis and classifying LN remains the renal biopsy. Renal biopsy, while invasive, offers critical insights into the underlying pathology of the kidney, allowing for accurate diagnosis and classification of LN. This information is essential for guiding treatment decisions and predicting prognosis. In this case, the renal biopsy confirmed the diagnosis of Class IV LN, characterized by diffuse proliferative glomerulonephritis, which helped guide the subsequent treatment strategy. The therapeutic management of LN during pregnancy presents a unique set of challenges due to the potential adverse effects of medications on both the mother and the developing fetus. The medications commonly used to treat LN, such as corticosteroids and immunosuppressants, can cross the placenta and potentially harm the fetus. Corticosteroids, while effective in controlling inflammation and suppressing the immune system, are associated with an increased risk of gestational diabetes, hypertension, pre-eclampsia, and premature rupture of membranes. Immunosuppressants, such as mycophenolate mofetil (MMF), can increase the risk of infections and fetal malformations, including cleft lip and palate, and heart defects. Therefore, treatment decisions must be carefully weighed, considering the severity of LN, the stage of pregnancy, and the potential risks and benefits of each medication. In some cases, the risks of treatment may outweigh the benefits, and a conservative approach may be preferred. In other cases, the severity of LN may necessitate aggressive treatment, even if it carries potential risks to the fetus. In this case, the patient's severe LN, with nephrotic syndrome, pleural effusion, and a hypercoagulable state, warranted prompt and aggressive treatment to prevent further deterioration of her condition and potential adverse maternal and fetal outcomes. She was treated with a combination of high-dose

corticosteroids and MMF, which is considered the standard of care for inducing remission in Class III/IV LN. The decision to use MMF in this case was made after careful consideration of the potential risks and benefits. MMF is a relatively new immunosuppressant, and its safety profile in pregnancy is not fully established. However, studies have shown that MMF is effective in treating LN and may be safer than other immunosuppressants, such as cyclophosphamide, which is associated with a higher risk of fetal malformations. Close monitoring of both maternal and fetal health is paramount during the treatment of LN in pregnancy. Regular follow-up visits with the healthcare team are essential to assess disease activity, monitor treatment response, and manage any potential complications. The frequency of monitoring and the specific tests performed will vary depending on the severity of LN, the stage of pregnancy, and the medications used. Regular blood pressure checks are essential to detect and manage hypertension, which is a common complication of LN and can contribute to kidney damage and other complications, such as pre-eclampsia. Regular urine tests are performed to monitor proteinuria and hematuria, which are indicators of LN activity. Blood tests are used to assess kidney function, measure inflammation markers, and monitor for potential side effects of medications. Fetal monitoring may include ultrasounds to assess fetal growth and development, and non-stress tests to monitor fetal well-being. The treatment of LN in pregnancy should be individualized based on the specific needs of the patient and the fetus. There is no one-size-fits-all approach, and treatment decisions must be made on a case-by-case basis. The management of LN in pregnancy is an evolving landscape, with new research constantly emerging. Recent studies have shed light on the complex interplay between pregnancy and LN, providing valuable insights into the diagnostic and therapeutic challenges associated with this condition. One area of active research is the identification of biomarkers that can predict LN flares during pregnancy. Anti-dsDNA antibodies are directed

against double-stranded DNA and are a hallmark of SLE. Elevated levels of anti-dsDNA antibodies have been associated with an increased risk of LN flares during pregnancy. Complement is a system of proteins that plays a role in the immune response. Low levels of complement components, such as C3 and C4, have been linked to an increased risk of LN flares during pregnancy. Several urinary biomarkers, such as proteinuria and hematuria, are used to monitor LN activity. New urinary biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1), are being investigated as potential predictors of LN flares during pregnancy. Another area of research is the development of safer and more effective treatment strategies for LN in pregnancy. Traditional immunosuppressants, such as cyclophosphamide, are associated with significant risks to the fetus, including teratogenicity and growth restriction. Newer immunosuppressants, such as MMF and tacrolimus, may offer a safer alternative, but their safety profiles in pregnancy are not fully established. Clinical trials are underway to evaluate the safety and efficacy of these newer immunosuppressants in pregnant women with LN. The results of these trials will help inform treatment decisions and improve outcomes for both mothers and their offspring. The management of LN in pregnancy requires a multidisciplinary approach, involving close collaboration between nephrologists, rheumatologists, obstetricians, and other specialists. This collaborative approach ensures comprehensive and coordinated care for pregnant women with LN, addressing both the SLE and pregnancy-related complications. The nephrologist plays a key role in diagnosing and managing LN, while the rheumatologist provides expertise in managing SLE. The obstetrician is responsible for monitoring the pregnancy and managing any pregnancy-related complications. Other specialists, such as cardiologists, pulmonologists, and neurologists, may be involved depending on the specific manifestations of LN and SLE. Regular communication and coordination between the healthcare team are essential to ensure that the

patient receives the best possible care. This multidisciplinary approach is critical for optimizing maternal and fetal outcomes in pregnant women with LN.<sup>16-18</sup>

The successful management of lupus nephritis (LN), especially in the context of pregnancy, hinges on a multidisciplinary approach and continuous long-term follow-up care. This collaborative strategy is essential to address the multifaceted nature of LN, its potential impact on various organ systems, and the intricate interplay between the disease, pregnancy, and overall maternal health. A multidisciplinary approach to LN care involves a team of healthcare professionals from various specialties, each contributing their expertise to provide comprehensive and coordinated care. The nephrologist plays a central role in diagnosing and managing LN, including monitoring kidney function, prescribing medications, and providing education and counseling on lifestyle modifications. The rheumatologist manages the overall SLE disease activity, including joint and skin manifestations, and collaborates with the nephrologist to optimize treatment strategies. In the case of pregnant women with LN, the obstetrician is crucial for monitoring the pregnancy, managing any pregnancy-related complications, and ensuring the safe delivery of a healthy baby. Depending on the specific manifestations of LN and SLE, other specialists, such as cardiologists, pulmonologists, and neurologists, may be involved in the care team. This multidisciplinary approach ensures that all aspects of the patient's condition are addressed, and that care is coordinated and consistent. Regular communication and collaboration between the healthcare team are essential to optimize patient outcomes. The concept of multidisciplinary care in LN is not static, it continues to evolve alongside advancements in our understanding of the disease and the development of new diagnostic and therapeutic modalities. As our knowledge of LN expands, we recognize its increasing complexity and its potential impact on various organ systems beyond the kidneys. This necessitates a more holistic approach to care, involving specialists from

different fields to address the diverse manifestations of the disease. The development of new diagnostic tools, such as novel biomarkers and imaging techniques, allows for earlier and more accurate diagnosis of LN, enabling timely intervention and preventing irreversible damage. These advancements require collaboration between specialists with expertise in interpreting and utilizing these new diagnostic modalities. The therapeutic landscape for LN is constantly evolving, with the emergence of new medications and treatment strategies. This necessitates a multidisciplinary approach to assess the risks and benefits of different treatment options and personalize care based on individual patient needs. The shift towards patient-centered care emphasizes the importance of shared decision-making and patient empowerment. This requires effective communication and collaboration between healthcare professionals and patients to develop individualized care plans that align with patient preferences and values. Technology plays an increasingly important role in facilitating multidisciplinary care for LN. Electronic health records (EHRs) allow for seamless sharing of patient information between healthcare providers, improving communication and coordination of care. Telehealth technologies enable remote consultations and monitoring, improving access to care for patients in remote areas or with limited mobility. Artificial intelligence (AI) and machine learning (ML) are also being explored for their potential to enhance multidisciplinary care in LN. AI-powered tools can analyze large datasets of patient information to identify patterns and predict disease progression, aiding in early diagnosis and personalized treatment decisions. Long-term follow-up care is crucial for individuals with LN, even after successful pregnancy and delivery, or during periods of remission. LN is a chronic condition that can recur or progress, potentially leading to chronic kidney disease and other complications. Continuous monitoring allows for early detection of any signs of disease recurrence or progression, enabling prompt intervention and preventing irreversible damage.

Regular assessments of renal function, blood pressure, and SLE disease activity are essential components of long-term follow-up care. The approach to long-term follow-up in LN is also evolving, with a greater emphasis on personalized care and patient empowerment. Patients are increasingly involved in their own care decisions, and their preferences and values are taken into consideration when developing long-term follow-up plans. Advances in our understanding of LN allow for better risk stratification, identifying individuals at higher risk of disease progression or complications. This enables personalized follow-up schedules and interventions tailored to individual risk profiles. The use of remote monitoring technologies, such as wearable sensors and home blood pressure monitors, allows for continuous monitoring of key parameters, enabling early detection of any deviations and timely intervention. The collection of patient-reported outcomes, such as quality of life and symptom burden, provides valuable insights into the patient's experience of living with LN and helps guide long-term management strategies. Patient education and empowerment are essential components of long-term follow-up care in LN. Educating patients about their condition, treatment options, and potential complications empowers them to actively participate in their own care and make informed decisions. Healthcare providers should provide clear and concise information about LN, including its causes, symptoms, and treatment options. They should also encourage patients to ask questions and express their concerns. Empowering patients to take an active role in their care can improve adherence to treatment regimens and long-term outcomes. Living with a chronic condition like LN can have a significant psychological impact, leading to anxiety, depression, and decreased quality of life. Long-term follow-up care should address the psychosocial needs of patients, providing support and resources to help them cope with the challenges of their condition. Healthcare providers should be sensitive to the emotional and social impact of LN and offer appropriate support and

referrals to mental health professionals if needed. Connecting patients with support groups and community resources can also provide valuable emotional support and practical assistance.<sup>19,20</sup>

#### 4. Conclusion

This case report highlights the complex interplay between pregnancy and lupus nephritis (LN), emphasizing the diagnostic and therapeutic challenges associated with this condition. The overlapping symptoms of LN with other pregnancy complications, the potential risks of medications to both the mother and fetus and the dynamic nature of the disease necessitate a nuanced and individualized approach to care. Renal biopsy remains the gold standard for confirming the diagnosis and classifying LN, guiding treatment decisions. The therapeutic management of LN during pregnancy requires careful consideration of the potential adverse effects of medications on both the mother and the developing fetus. Close monitoring of both maternal and fetal health is paramount during the treatment of LN in pregnancy. The treatment of LN in pregnancy should be individualized based on the specific needs of the patient and the fetus. Recent research has shed light on the complex interplay between pregnancy and LN, providing valuable insights into the diagnostic and therapeutic challenges associated with this condition. The identification of biomarkers that can predict LN flares during pregnancy is an area of active research. Another area of research is the development of safer and more effective treatment strategies for LN in pregnancy. The management of LN in pregnancy requires a multidisciplinary approach, involving close collaboration between nephrologists, rheumatologists, obstetricians, and other specialists. The successful management of LN, especially in the context of pregnancy, hinges on a multidisciplinary approach and continuous long-term follow-up care. This collaborative strategy is essential to address the multifaceted nature of LN, its potential impact on various organ systems, and the intricate interplay between the disease, pregnancy, and overall maternal

health. Long-term follow-up care is crucial for individuals with LN, even after successful pregnancy and delivery, or during periods of remission. Continuous monitoring allows for early detection of any signs of disease recurrence or progression, enabling prompt intervention and preventing irreversible damage. Patient education and empowerment are essential components of long-term follow-up care in LN. Long-term follow-up care should address the psychosocial needs of patients, providing support and resources to help them cope with the challenges of their condition.

#### 5. References

1. Younis D, Shemies R, Zakaria MM, Omar SA, Mosbah A, El-Kannishy G, et al. Urinary congophilin as a predictive biomarker of lupus nephritis in pregnant and non-pregnant women with systemic lupus erythematosus. *Lupus*. 2025; 34(2): 149–56.
2. Cardwell FS, Elliott SJ, Barber MR, Cheema K, George S, Boucher A, et al. Investigating how patients with lupus nephritis access and trust health information: Results from a Canadian survey of patients with lupus nephritis. *Lupus*. 2025; 34(2): 217–9.
3. Cannon LA, Wenderfer SE, Lewandowski LB, Cooper JC, Goilav B, Knight AM, et al. Use of EuroLupus cyclophosphamide dosing for the treatment of lupus nephritis in childhood-onset systemic lupus erythematosus in north America. *J Rheumatol*. 2022; 49(6): 607–14.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. *Kidney Int*. 2024; 105(1S): S1–69.
5. de Jesus GRR, Do Nascimento AP, Porto LC, De Jesús NR, Levy RA, Klumb EM. 68 sFlt-1, PlGF and VEGF in differential diagnosis between preeclampsia and systemic lupus nephritis. *Pregnancy Hypertens*. 2016; 6(3): 170.

6. Bramham K, Soh MC, Nelson-Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. *Lupus*. 2012; 21(12): 1271–83.
7. Webster P, Wardle A, Bramham K, Webster L, Nelson-Piercy C, Lightstone L. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. *Lupus*. 2014; 23(11): 1192–6.
8. Chen TK, Gelber AC, Witter FR, Petri M, Fine DM. Renal biopsy in the management of lupus nephritis during pregnancy. *Lupus*. 2015; 24(2): 147–54.
9. Koh JH, Ko HS, Lee J, Jung SM, Kwok S-K, Ju JH, et al. Pregnancy and patients with preexisting lupus nephritis: 15 years of experience at a single center in Korea. *Lupus*. 2015; 24(7): 764–72.
10. Chen D, Yuan S, Lao M, Zhan Y, Xu H, Liang L, et al. Umbilical arterial Doppler ultrasonography predicts late pregnancy outcomes in patients with lupus nephritis: a multicenter study from southern China. *Lupus*. 2019; 28(11): 1312–9.
11. Attia DH, Mokbel A, Haggag HM, Naeem N. Pregnancy outcome in women with active and inactive lupus nephritis: a prospective cohort study. *Lupus*. 2019; 28(7): 806–17.
12. Lucas A, Eudy AM, Gladman D, Petri M, Urowitz M, Wyatt CM, et al. The association of lupus nephritis with adverse pregnancy outcomes among women with lupus in North America. *Lupus*. 2022; 31(11): 1401–7.
13. Attia DH, Mokbel A, Mohamed MF, Haggag HM. Long-term impact of pregnancy on renal function among Egyptian women with lupus nephritis: a case control study. *Lupus*. 2023; 32(7): 842–54.
14. Elahi T, Ahmed S, Mubarak M, Ahmed E. Maternal and fetal outcomes in pregnancy complicated by pre-existing lupus nephritis: Insights from a developing country Pakistan. *Lupus*. 2024; 33(7): 728–36.
15. Normand G, Sens F, Puthet J, Jourde-Chiche N, Lemoine S, Chauveau D, et al. Not only disease activity but also chronic hypertension and overweight are determinants of pregnancy outcomes in patients with systemic lupus erythematosus. *Lupus*. 2019; 28(4): 529–37.
16. Bisgaard H, Jacobsen S, Tvede N, Langhoff-Roos J. Pregnancy complications in a patient with systemic lupus erythematosus and lupus nephritis. *Ugeskr Laeger*. 2014; 176(29): V01140044.
17. Kirsanova TV, Kravchenko NF, Balakireva AI. Case of neonatal lupus in one of two children of dichorial diamniotic pregnancy in a woman with unrecognized systemic lupus erythematosus and lupus nephritis. *Nephrol (St-Petersbg)*. 2020; 24(2): 88–95.
18. Oishi Y, Ikeuchi H, Hamatani H, Nakasatomi M, Sakairi T, Kaneko Y, et al. Pregnancy outcomes in patients with systemic lupus erythematosus with or without a history of lupus nephritis. *Clin Exp Nephrol*. 2021; 25(8): 835–43.
19. Thaha M, Alsagaff MY, Dwi Suryantoro S, Rizky Hayati M, Susilo H, Nur Rosyid A, et al. High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: a systematic review and meta-analysis. *F1000Res*. 2022; 11: 543.
20. Lee J-YE, Mendel A, Askanase A, Bae S-C, Buyon JP, Clarke AE, et al. Systemic lupus erythematosus women with lupus nephritis in pregnancy therapeutic challenge (SWITCH): The systemic lupus international collaborating clinics experience. *Ann Rheum Dis*. 2023; 82(11): 1496–7.